MANA-312: Acute Myeloid Leukemia
T cells targeting multiple tumor antigens are the cornerstones of Mana Therapeutics. These targets are present in a variety of cancers - including blood cancers.
Someone in the US dies from a blood cancer every 9 minutes
Standard of care treatments - chemotherapy and radiation - have significant side effects, and, for a significant subset of patients, are not curative. There has been great promise arising from the advent of immune-based therapies - but while it has been successful for some cancers, there is currently no suitable immunotherapy for one particularly deadly one: AML, or acute myeloid leukemia.
For more than two decades, mortality rates for AML have remained unchanged. There are more than 19,000 cases of AML each year in the US alone, resulting in more than 10,000 deaths per year.